This report aims to estimate the impacts of providing remdesivir as an outpatient treatment for COVID-19 in Canada on health system costs and health outcomes.

The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population in Canada was infected with COVID-19.

This report aims to estimate the impacts of providing remdesivir as an inpatient treatment for COVID-19 in Canada on health system costs and health outcomes.

The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population in Canada was infected with COVID-19.

This report aims to estimate the impacts of providing tocilizumab as a treatment for COVID-19 in Canada on health system costs and health outcomes.

The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population in Canada was infected with COVID-19.
 

This report aims to estimate the impacts of providing nirmatrelvir-ritonavir as an outpatient treatment for COVID-19 in Canada on health system costs and health outcomes.

The analyses presented in this report were conducted using 2022 data, which represented a year of the pandemic when a large proportion of the population was infected with COVID-19
 

A retrospective cohort study was conducted to determine the outpatient utilization of nirmatrelvir-ritonavir and remdesivir in Canada. For nirmatrelvir-ritonavir, administrative health databases from Alberta, British Columbia, Manitoba, Ontario, Quebec, and Saskatchewan were used. For remdesivir, aggregate data for outpatient remdesivir prescriptions from the Ontario Ministry of Health, the Saskatchewan Health Authority, and the Winnipeg Regional Health Authority were obtained. Outpatient remdesivir infusions are not routinely captured in prescription drug claims.

Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy and safety of tocilizumab for the treatment of COVID-19. We also characterized which hospitalized patients are most likely to benefit from treatment with tocilizumab.

Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy, effectiveness, and safety of remdesivir for the treatment of COVID-19 in nonhospitalized adult patients from settings within the health care systems in Canada or from countries with economies similar to Canada. We also characterized which nonhospitalized patients are most likely to benefit from treatment with remdesivir.

Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy and safety of remdesivir for the treatment of COVID-19 in hospitalized adult and adolescent patients from settings within the health care systems in Canada or from countries with economies similar to Canada. We also characterized which hospitalized patients are most likely to benefit from treatment with remdesivir.